european medicines agency glp-1 vision loss recommendation november 2025 USP provides resources to ensure purity EMA finds no link between

A systematic review of 76 different clinical trials looking at the risk of gallbladder disease for people taking GLP-1 agonists showed that there was an increase in risk for the development of gallbladder disease when taken at higher doses for long periods of time

For example, one study found that L-carnitine supplementation improved c ycling performance in cyclists by 11%

The DPP4 inhibitor sitagliptin increases active GLP-1 levels from human islets and may increase islet cell survival prior to transplantation

controlled human safety data is limited and incomplete

Stress, poor sleep, hormonal imbalances, and the standard American diet can disrupt metabolic health at any age

1 Data like this is important because it determines whether these drugs should be looked at as a permanent aspect of a patients lifestyle or something that kickstarts a weight-loss phase